Aspen Neuroscience, based in San Diego, CA, is a pioneering company that leverages stem cell biology and genomics to develop personalized cell therapy for Parkinson's disease. Their groundbreaking approach involves the use of autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy, aiming to reverse the effects of the disease. With a focus on both idiopathic and genetically linked forms of Parkinson's, Aspen Neuroscience is at the forefront of advancing innovative treatments for this debilitating condition.
Driven by a mission to turn back the clock on Parkinson's disease, Aspen Neuroscience is developing autologous IPSC-derived cell replacement therapies. Their cutting-edge technology and research have garnered recognition, including receiving the 2023 Biocom California Life Science Catalyst Award and obtaining Fast Track Designation from the FDA for their investigational cell therapy, ANPD001. With a dedicated team of experts and a commitment to advancing the field, Aspen Neuroscience is revolutionizing the treatment landscape for Parkinson's disease.
Generated from the website